Key result
Cinnamic acid pre-treatment significantly mitigated methotrexate-induced lung fibrosis in rats, reducing collagen content by 67% and improving oxidative and inflammatory markers comparably to pirfenidone.
Why the study?
Lung fibrosis is characterized by excessive scar tissue accumulation and destruction of lung architecture, and this study examined the potential shielding influence of cinnamic acid against methotrexate-induced lung fibrosis.
Does cinnamic acid prevent methotrexate-induced lung fibrosis in rats?
Does cinnamic acid prevent methotrexate-induced lung fibrosis in rats?
Cinnamic acid mitigates methotrexate-induced lung fibrosis in rats with efficacy comparable to pirfenidone, highlighting its potential as a prophylactic adjuvant therapy.
Cinnamic acid shows preclinical promise vs MTX fibrosis; leaves open translation to human prophylaxis.
PURPOSE: Lung fibrosis is a heterogeneous lung condition characterized by excessive accumulation of scarred tissue, leading to lung architecture destruction and restricted ventilation. The current work was conducted to examine the probable shielding influence of cinnamic acid against lung fibrosis induced by methotrexate. METHODS: days of the experiment. Pirfenidone (50 mg/kg/day) was used as a standard drug. At the end of the experiment, oxidative parameters (malondialdehyde, myeloperoxidase, nitric oxide, and total glutathione) and inflammatory mediators (tumor necrosis factor-α and interleukin-8), as well as transforming growth factor-β and collagen content, as fibrosis indicators, were measured in lung tissue. RESULTS: Our results revealed that cinnamic acid, as pirfenidone, effectively prevented the methotrexate-induced overt histopathological damage. This was associated with parallel improvements in oxidative, inflammatory, and fibrotic parameters measured. The outcomes of cinnamic acid administration were more or less the same as those of pirfenidone. In conclusion, pre-treatment with cinnamic acid protects against methotrexate-induced fibrosis, making it a promising prophylactic adjuvant therapy to methotrexate and protecting against its possible induction of lung fibrosis.
No takes yet. Share an insight, caveat, or question.
Abdalhameid et al. (2023) studied Methotrexate-induced lung fibrosis. Cinnamic acid vs. Methotrexate control and Pirfenidone (50 mg/kg/day) was evaluated on Lung collagen content (67% depletion, p=<0.05). Cinnamic acid pre-treatment significantly mitigated methotrexate-induced lung fibrosis in rats, reducing collagen content by 67% and improving oxidative and inflammatory markers comparably to pirfenidone.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: